1021155-39-4
Chemical Structure
WYRGRL
- CAS No.: 1021155-39-4
- Formula:C40H59N13O8
- Molecular Weight:849.98
InChIKey: AWWPAAKKYFBART-QDNWXXHKSA-N
SMILES: O=C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)[C@H](CC2=CNC3=CC=CC=C23)N
Biological Activity: WYRGRL is a selective, high-affinity collagen type II-binding peptide with a IC50 of 140 nM. Collagen type II is the most abundant and specific structural protein in the extracellular matrix of articular cartilage. WYRGRL can precisely target small-molecule compounds such as Dexamethasone (HY-14648) and nanocarrier-engineered exosomes to cartilage, significantly enhancing their therapeutic effects on osteoarthritis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
WYRGRL | 99.88% | WYRGRL is a selective, high-affinity collagen type II-binding peptide with a IC50 of 140 nM. Collagen type II is the most abundant and specific structural protein in the extracellular matrix of articular cartilage. WYRGRL can precisely target small-molecule compounds such as Dexamethasone (HY-14648) and nanocarrier-engineered exosomes to cartilage, significantly enhancing their therapeutic effects on osteoarthritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Formica FA, et al. Cartilage-targeting dexamethasone prodrugs increase the efficacy of dexamethasone. J Control Release. 2019;295:118-129. [Content Brief]
- [2]. Wan J, et al. Injectable photocrosslinking spherical hydrogel-encapsulated targeting peptide-modified engineered exosomes for osteoarthritis therapy. J Nanobiotechnology. 2023;21(1):284. Published 2023 Aug 21. [Content Brief]
